Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GenVec - GNVC -- Ignore unavailable to you. Want to Upgrade?

To: Savant who wrote (60)	11/12/2014 6:29:06 PM
From: Gary Mohilner	Respond to of 106

GNVC could explode on any really positive future news on any of these drugs if they are in people. It's nice to know that things are looking good with RSV, but does anyone have an idea how close we are to human trials. Of course our hearing drug has begun in trial, now the question is, how long will it be before we see any news. I suspect that Novartis will speak up at the appropriate opportunity if they have evidence of hearing improvement, but we have no idea how many dose escalations will be needed to achieve an improvement in hearing. The optimal dosage could be substantially higher, especially if they don't encounter negative side effects. While I'm sure their will be dilution, if it's not extensive, this stock could be triple digit on approval of the hearing drug IMHO. Gary